Browsing by Author "Vicentini, Daniel"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Clinical and molecular characterization of ESBL-producing enterobacteria isolated from bacteremia in a university
    (2011) García Cañete, Patricia; Rubilar P., Carla; Vicentini, Daniel; Román Guiraldes, Juan Carlos; Leon C., Eugenia; Munoz C., Gabriel; Dominguez Y., Mariana; Gonzalez R., Gerardo; Bello T., Helia; Labarca L., Jaime
  • No Thumbnail Available
    Item
    Effect of Low-Dose Statins in Addition to Standard Therapy on Brain Perfusion and Neurocognitive Performance in Patients with Major Depressive Disorder
    (2022) Massardo, Teresa; Quintana, Juan C.; Risco, Luis; Corral, Sebastian; Spuler, Jane; Vicentini, Daniel; Castro-Munoz, Gabriel; Riedel, Byron; Villa, Carolina; Pereira, Jaime I.
    Introduction: Major depressive disorder (MDD) is a prevalent condition which has a well-known association with ischemic cardiomyopathy, probably explained by an inflammatory mediator mechanism. Statins, besides reducing cholesterol production, have pleiotropic effects including anti-inflammatory activity. The goal was to evaluate the effect of statins as an addition to standard therapy on mood status, brain perfusion, and neurocognitive performance in MDD. Methods: We studied 20 MDD patients with brain single-photon emission tomography and Cambridge Neuropsychological Test Automated Battery (CANTAB), half randomized to 10 mg of Rosuvastatin or placebo, in addition to selective serotonin reuptake inhibitors (SSRIs) therapy and being reevaluated 3 months later. The images were compared using Statistical Parametric Mapping; clinical scores (Hamilton Depression Score with 17 items and Beck's Depression Inventory) as well as neurocognitive parameters were applied as covariances (CoV) to estimate regional cerebral blood flow (rCBF) changes with both therapies. Results: Clinical scores decreased in both groups (p = 0.0001); Beck's presented a larger decrease with statins. We observed significantly rCBF changes expressed as significant larger clusters of voxels (p < 0.05) in the pre/subgenual anterior cingulate plus orbitofrontal cortex and a small area in the posterior cingulate gyrus in the statins group, whereas it was not observed with placebo, when using clinical scores as CoV. A similar pattern of rCBF changes was present with emotions recognition, attentional, paired associates learning, spatial planning, and working memory tasks. Conclusion: Short-term use of low-dose statins in MDD patients under SSRIs results in important rCBF changes in key mood associated areas to improvement in neurocognitive performance. These findings, even though demonstrated in a small sample, could open a new therapeutic tool in the comprehensive management of this disorder.
  • Thumbnail Image
    Item
    Identification of Statin’s Action in a Small Cohort of Patients with Major Depression
    (2021) Thakkar, Ishani; Massardo, Teresa; Pereira, Jaime; Quintana, Juan Carlos; Risco, Luis; Saez, Claudia G.; Corral, Sebastián; Villa, Carolina; Spuler, Jane; Olivares, Nixa; Valenzuela, Guillermo; Castro, Gabriel; Riedel, Byron; Vicentini, Daniel; Muñoz, Diego; Lastra, Raúl; Rodriguez-Fernandez, Maria
    Statins are widely used as an effective therapy for ischemic vascular disorders and employed for primary and secondary prevention in cardiac and cerebrovascular diseases. Their hemostatic mechanism has also been shown to induce changes in cerebral blood flow that may result in neurocognitive improvement in subjects with Major Depressive Disorder. Behavioral data, various blood tests, and resting-state brain perfusion data were obtained at the start of this study and three months post-therapy from a small cohort of participants diagnosed with Major Depressive Disorder. Subjects received either rosuvastatin (10 mg) or placebo with their standard selective serotonin reuptake inhibitors therapy. At the end of the study, patients using rosuvastatin reported more positive mood changes than placebo users. However, standard statistical tests revealed no significant differences in any non-behavioral variables before and after the study. In contrast, feature selection techniques allowed identifying a small set of variables that may be affected by statin use and contribute to mood improvement. Classification models built to assess the distinguishability between the two groups showed an accuracy higher than 85% using only five selected features: two peripheral platelet activation markers, perfusion abnormality in the left inferior temporal gyrus, Attention Switching Task Reaction latency, and serum phosphorus levels. Thus, using machine learning tools, we could identify factors that may be causing self-reported mood improvement in patients due to statin use, possibly suggesting a regulatory role of statins in the pathogenesis of clinical depression.
  • No Thumbnail Available
    Item
    Rhabdomyolysis and severe hypercalcemia. Report of one case
    (SOC MEDICA SANTIAGO, 2019) Huidobro E, Juan Pablo; Santander, Jaime; Vicentini, Daniel; Jara, Aquiles
    Rhabdomyolysis (RD) is the process that leads to cell destruction of striated muscle. Causes include inherited metabolic defects or acquired disorders. RD is frequently associated with acute kidney injury (AKI) and disorders of calcium metabolism. We report a 33 year old man that after amphetamine consumption and an uninterrupted 3,000 km driving presented vomiting, muscle pain and dark urine. He had elevated creatinkinase levels, severe hypocalcemia and an acute renal failure. He was treated with hemodialysis and calcitriol. He was transferred to our hospital and on admission a serum calcium of 18 mg/dl was detected. He continued on hemodialysis, recovering renal function and with normalization of creatinkinase levels and serum calcium level.